NASDAQ: DRNA - Dicerna Pharmaceuticals, Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Dicerna Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Dicerna Pharmaceuticals, Inc.

Биофармацевтическая компания Dicerna Pharmaceuticals, Inc. специализируется на открытии и разработке фармацевтических препаратов на основе интерференции рибонуклеиновой кислоты (РНКи). Компания разрабатывает фармацевтические препараты с использованием своей платформы GalXC RNAi для лечения заболеваний печени, включая редкие заболевания, вирусные инфекционные заболевания, хронические заболевания печени и кардиометаболические заболевания.

more details
Его основные программы развития включают недосиран для лечения первичной гипероксалурии; RG6346 для лечения хронической инфекции вируса гепатита B; и программа лечения нераскрытого редкого заболевания печени. В программы развития компании также входят программы DCR-A1AT; и программа лечения нейродегенерации и боли. Dicerna Pharmaceuticals, Inc. имеет стратегическое сотрудничество с Novo Nordisk A \ u002FS, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. и Boehringer Ingelheim International GmbH. Компания была основана в 2006 году, ее штаб-квартира находится в Лексингтоне, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2014-01-30
ISIN US2530311081
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://dicerna.com
Цена ао 37.96
Change price per day: 0% (38.22)
Change price per week: 0% (38.22)
Change price per month: 0% (38.22)
Change price per 3 month: 0% (38.22)
Change price per half year: 0% (38.22)
Change price per year: 0% (38.22)
Change price per 3 year: +0.6849% (37.96)
Change price per 5 year: +43.58% (26.62)
Change price per 10 year: +94.6% (19.64)
Change price per year to date: 0% (38.22)
All parameters

Underestimation

Title Value Grade
P/S 15.2 1
P/BV 27.7 1
P/E 0 0
EV/EBITDA -20.9 0
Total: 1.5

Efficiency

Title Value Grade
ROA, % -17.12 0
ROE, % -95.22 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.5518 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 8286.96 10
Yield Ebitda, % 99.83 9
Yield EPS, % -41.61 0
Total: 5.8
More

Institutions Volume Share, %
RTW INVESTMENTS, LLC 7521859 9.68
BlackRock Fund Advisors 5620264 7.36
SSGA Funds Management Inc 4083964 5.25
Bain Capital Life Sciences Investors, LLC 3080237 3.96
Aquilo Capital Management, LLC 1813392 2.33
Candriam Belgium 1143680 1.5
Polar Capital LLP 1084813 1.4
Hartford Funds Management Company, LLC 891613 1.15
Federated MDTA LLC 853626 1.1
Advanced Series Trust 646199 0.84
Invesco Capital Management LLC 605461 0.78
Dafna Capital Management LLC 510756 0.66
AXA Investment Managers UK Ltd 319319 0.43
Parkman Healthcare Partners LLC 304686 0.39
Voya Investments, LLC 302733 0.39
Global X Management Company LLC 253113 0.33
SILVERARC CAPITAL MANAGEMENT, LLC 229892 0.3
Brighthouse Investment Advisers, LLC 225796 0.29
Driehaus Capital Management LLC 198720 0.26
Lyxor International Asset Management S.A.S. 178369 0.23
MML Investment Advisers, LLC 169354 0.23
Eagle Health Investments LP 161125 0.21
Prudential Retirement Services 143262 0.19
Evolutionary Tree Capital Management LLC 141324 0.18
Schroder Investment Management Limited 140884 0.18
UBS Asset Management (Americas) Inc 119782 0.15
Arctic Asset Management AS 97907 0.13
Bellevue Asset Management AG 68000 0.09
AMG Funds LLC 65706 0.09
SunAmerica Asset Management, LLC 48970 0.06
Allianz Global Investors 42967 0.06
Migdal Mutual Funds Ltd 28720 0.04
Allianz Global Investors U.S. LLC 26035 0.03
IP Unsure (Only US OE Use) 18034 0.02
361 Capital, LLC 13440 0.02
AXA Investment Managers Paris 10923 0.01
DNB Asset Management AS 8015 0.01
Severin Investments, LLC 7650 0.01
Santander Private Banking Gestión SGIIC 4164 0.01
Glenmede Investment Management, LP 1200 0
Peroni Portfolio Advisors, Inc 500 0

ETFShare, %Profitability for 1 year, %Dividends, %
ProShares UltraShort Nasdaq Biotechnology 0.18 -40.36 1.76
0.18-40.361.76



Head Job title Payment Year of birth
Dr. Douglas M. Fambrough III Co-Founder, CEO, Pres & Director 939.47k 1969 (56 years)
Mr. Douglas W. Pagan Chief Financial Officer 515.65k 1972 (53 years)
Mr. James B. Weissman Exec. VP & COO 648.77k 1962 (63 years)
Dr. Bob D. Brown Exec. VP of R&D and Chief Scientific Officer 695.89k 1965 (60 years)
Dr. Shreeram Aradhye M.D. Exec. VP & Chief Medical Officer 434.4k 1963 (62 years)
Dr. Mark Behlke Co-Founder & Member of Scientific Advisory Board N/A
Ms. Ling Zeng J.D. Chief Legal Officer & Sec. N/A 1969 (56 years)
Prof. John J. Rossi Ph.D. Co-Founder & Chairman of Scientific Advisory Board 1947 (78 years)
Ms. Kristen K. Sheppard Esq., J.D. Sr. VP of Investor Relations & Corp. Communications
Ms. Susan Birdsey SPHR Sr. VP of HR

Address: United States, Lexington, MA , 75 Hayden Avenue - open in Google maps, open in Yandex maps
Website: http://dicerna.com